Prostate News Archive
15-Oct-2008
The Case For Prostate-Specific Antigen Screening Starting At Age 40 (Medical News Today)
UroToday.com - Dr. Robert Nadler, of Northwestern University, wrote an excellent editorial in a recent issue of Cancer regarding the commencement of prostate cancer (CaP) screening at age 40. The National Comprehensive Cancer Care Network (NCCN) recommends an initial PSA at age 40 for men of all races. The frequency of subsequent PSA tests would depend on the initial level. Long-Term Assessment Of Prostate Cancer Progression Free Survival (Medical News Today)
UroToday.com - In the online version of The prostate, Dr. Robert W. Veltri and his colleagues from Johns Hopkins University reported on the correlation of molecular pathways and progression-free survival (PFS) in prostate cancer (CaP). Testosterone Therapy In Hypogonadal Men And Potential Prostate Cancer Risk: A Systematic Review (Medical News Today)
UroToday.com - In the online edition of the International Journal of Impotence Research, Dr. R. Shabsigh and his associates presented a systematic review of testosterone therapy for hypogonadism and its relation to prostate cancer (CaP). The data did not suggest that testosterone therapy is associated with increased CaP risk in hypogonadal men nor demonstrate a consistent effect on PSA levels. New Risk Factor For Prostate Cancer (Science Daily)
The greater the levels of a protein called Insulin-like Growth Factor-1 (IGF-1), the greater the risk of prostate cancer, a new study has found. Rapaflo OK'd to treat enlarged prostate (Moldova.org)
The U.S. Food and Drug Administration has approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia.Benign prostatic hyperplasia (also known as an enlarged prostate gland) can seriously impact the quality of life of men as they age, said George Benson, deputy director of the FDA's division of reproductive and urological products. This product will ...
Back to Prostate News Archive
